Elucidation of the metabolic pathway of S-equol in rat, monkey and man

Food and Chemical Toxicology

Volumn 50, Issue 6, 2012, Pages 2074-2083

  Schwen, Richard J ^a   Nguyen, Linh ^b   Jackson, Richard L ^a  

^a Ausio Pharmaceuticals LLC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Hepatocytes; Metabolism; Metabolite identification; S equol

Indexed keywords

DRUG METABOLITE; EQUOL; EQUOL 4' GLUCURONIDE; EQUOL 7 SULFATE; EQUOL 7 SULFATE 4' GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; FECES ANALYSIS; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER CELL; MALE; MASS SPECTROMETRY; NONHUMAN; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; URINALYSIS;

ANIMALS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYOPRESERVATION; EQUOL; FECES; GLUCURONIDES; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SULFATES; TISSUE DISTRIBUTION;

MACACA FASCICULARIS; RATTUS;

EID: 84860127103     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.03.048     Document Type: Article

References (20)

1. Adlercreutz H., Honjo H., Higashi A., Fotsis T., Hämäläinen E., Hasegawa T., Okada H. Urinary excretion of lignans and isoflavonoid phyto-estrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 1991, 54:1093-1100.
2. Atkinson C., Frankenfeld C.L., Lampe J.W. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp. Biol. Med. 2005, 230:155-170.
3. Axelson M., Sjövall J., Gustafsson B.E., Setchell K.D.R. Soya - a dietary source of the non-steroidal oestrogen equol in man and animals. J. Endocrinol. 1984, 102:49-56.
4. Boxenbaum H., DiLea C. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Phcl. 1995, 35:957-966.
5. Gu L., House S.E., Prior R.L., Fang N., Ronis M.J.J., Clarkson T.B., Wilson M.E., Badger T.M. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J. Nutr. 2006, 136:1215-1221.
6. Hsieh R.W., Rajan S.S., Sharma S.K., Guo Y., DeSombre E.R., Mrksich M., Greene G.L. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J. Biol. Chem. 2006, 281:17909-17919.
7. Ishiwata N., Melby M., Mizuno S., Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 2009, 16:141-148.
8. Jackson R.L., Greiwe J.S., Desai P.B., Schwen R.J. Single-dose and multi-dose 14 day pharmacokinetics studies of S-equol, a potent non hormonal, estrogen receptor β agonist being developed for the treatment of menopausal symptoms. Menopause 2011, 18:185-193.
9. Minutolo F., Macchia M., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor β ligands: recent advances and biomedical applications. Med. Res. Rev. 2011, 31:364-442.
10. Muthyala R.S., Ju Y.H., Sheng S., Williams L.D., Doerge D.R., Katzenellenbogen B.S., Helferich W.G., Katzenellenbogen J.A. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg. Med. Chem. 2004, 12:1559-1567.
11. Plomley J., Jackson R.L., Schwen R.J., Greiwe J.S. Development of liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods for determination of free and total S-equol in human plasma and urine. J. Pharmaceut. Biomed. Anal. 2011, 55:125-134.
12. Pugazhendhi D., Watson K.A., Mills S., Botting N., Pope G.S., Darbre P.D. Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells. J. Endocrinol. 2002, 197:503-515.
13. Rossouw (for the Writing Group) J.E. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333.
14. Rüfer C.E., Glatt H., Kulling S.E. Structural elucidation of hydroxylated metabolites of the isoflavone equol by gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry. Drug. Metab. Dispos. 2006, 34:51-60.
15. Setchell K.D.R., Brown N.M., Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 2002, 132:3577-3584.
16. Setchell K.D., Clerici C. Equol: history, chemistry, and formation. J. Nutr. 2010, 140:1355S-1362S.
17. Setchell K.D.R., Clerici C., Lephart E.D., Cole S.J., Heenan C., Castellani D., Wolfe B.E., Nechemias-Zimmer L., Brown N.M., Lund T.D., Handa R.J., Heubi J.E. S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am. J. Clin. Nutr. 2005, 81:1072-1079.
18. Setchell K.D.R., Zhao X., Jha P., Heubi J.E., Brown N.M. The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope labeled tracers. Am. J. Clin. Nutr. 2009, 90:1029-1037.
19. Setchell K.D.R., Zhao X., Shoaf S.E., Ragland K. The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women. J. Nutr. 2009, 139:2037-2043.
20. Tousen Y., Ezaki J., Fujii Y., Ueno T., Nishimuta M., Ishimi Y. Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause 2011, 18:563-574.